C. Hofmeister

C. Hofmeister, C. Czerlanis, P. Stiff, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma

C. Hofmeister, B. Emami, G. Petruzzelli, 2001, Cancer.

Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche

Jiwang Zhang, C. Hofmeister, P. Stiff, 2007, Bone Marrow Transplantation.

LENALIDOMIDE AND VORINOSTAT MAINTENANCE AFTER AUTOLOGOUS TRANSPLANT IN MULTIPLE MYELOMA-LONG TERM FOLLOW-UP.

C. Hofmeister, D. Benson, Y. Efebera, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer

C. Hofmeister, Joseph I. Clark, J. Greene, 2012, Medical Oncology.

BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.

C. Hofmeister, L. Andritsos, D. Benson, 2019, Biology of Blood and Marrow Transplantation.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

J. Byrd, C. Hofmeister, F. Pichiorri, 2017, Leukemia & lymphoma.

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma

C. Hofmeister, R. Vij, J. Laubach, 2016, British journal of haematology.

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

C. Hofmeister, A. Krishnan, F. Pichiorri, 2021, Molecular therapy oncolytics.

Most multiple myeloma patients have low testosterone

C. Hofmeister, D. Benson, Y. Efebera, 2018, Leukemia & lymphoma.

Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.

J. Byrd, C. Hofmeister, C. Chen, 2014, Journal of pharmaceutical and biomedical analysis.

Evaluation of pulmonary infiltrates in patients after stem cell transplantation

C. Hofmeister, P. Stiff, S. Scaglione, 2005, Hematology.

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents

Nisha S Joseph, C. Hofmeister, S. Lonial, 2018, Cancer.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2016, Blood.

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Michael A. Freitas, J. Byrd, C. Croce, 2017, The Journal of experimental medicine.

Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

K. Owzar, C. Hofmeister, R. Vij, 2015 .

Analysis of Second Primary Malignancies (SPMs) in CALGB (Alliance)/ECOG/BMT CTN 100104

K. Owzar, C. Hofmeister, R. Vij, 2015 .

Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions

C. Hofmeister, G. Nuovo, F. Pichiorri, 2017, Applied immunohistochemistry & molecular morphology : AIMM.

XRCC1‐mediated DNA repair is associated with progression‐free survival of multiple myeloma patients after autologous stem cell transplant

C. Hofmeister, M. Phelps, M. Poi, 2019, Molecular carcinogenesis.

Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life.

C. Hofmeister, S. Lonial, J. Kaufman, 2021, Transplantation and cellular therapy.

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Nisha S Joseph, C. Hofmeister, S. Lonial, 2019, Blood Cancer Journal.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

C. Hofmeister, S. Trudel, D. Reece, 2018, Blood.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

M. Caligiuri, C. Hofmeister, S. Jagannath, 2012, Blood.

A phase 1 trial of the anti-KIR antibody IPH 2101 in patients with relapsed / refractory multiple myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2012 .

Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant

C. Hofmeister, N. Mahmud, B. Vemu, 2020, British journal of clinical pharmacology.

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas

C. Hofmeister, L. Andritsos, D. Benson, 2019, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

C. Hofmeister, R. Garzon, G. Marcucci, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

M. Dimopoulos, C. Hofmeister, J. Laubach, 2019, European journal of haematology.

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

C. Hofmeister, P. Richardson, M. Liedtke, 2018, British journal of haematology.

A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients

C. Hofmeister, M. Phelps, D. Sborov, 2018, AntiCancer Research.

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant

C. Hofmeister, E. Hade, D. Mould, 2018, CPT: pharmacometrics & systems pharmacology.

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

C. Hofmeister, M. Phelps, M. Poi, 2014 .

Retrospective utility of bronchoscopy after hematopoietic stem cell transplant

C. Hofmeister, C. Czerlanis, P. Stiff, 2006, Bone Marrow Transplantation.

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

H. W. Slone, C. Hofmeister, D. Welling, 2021, Laryngoscope investigative otolaryngology.

Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial

C. Hofmeister, A. Krishnan, W. Wachsman, 2021, Frontiers in Immunology.

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

K. Owzar, C. Hofmeister, R. Vij, 2010 .

Natural history of multiple myeloma patients refractory to venetoclax: A single center experience

Nisha S Joseph, C. Hofmeister, S. Lonial, 2020, American journal of hematology.

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

M. Beksac, H. Goldschmidt, C. Hofmeister, 2020, Leukemia.

Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma

J. Byrd, C. Hofmeister, D. Benson, 2015, Bone Marrow Transplantation.

Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)

C. Hofmeister, R. Garzon, G. Lozanski, 2016 .

Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

K. Coombes, C. Hofmeister, R. Garzon, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.

C. Hofmeister, G. Phillips, G. Marcucci, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma

C. Hofmeister, F. Pichiorri, R. Baiocchi, 2017, Molecular therapy oncolytics.

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

C. Hofmeister, E. Baloglu, C. Cubitt, 2016 .

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

A. Azmi, C. Hofmeister, D. Siegel, 2014 .

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing

C. Hofmeister, M. Phelps, C. Coss, 2021, European Journal of Drug Metabolism and Pharmacokinetics.

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.

C. Hofmeister, S. Lonial, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

K. Owzar, C. Hofmeister, V. Hárs, 2010 .

Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.

C. Hofmeister, E. Drea, L. Andritsos, 2019, Leukemia research.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy

C. Hofmeister, A. Satoskar, L. Andritsos, 2016, Bone Marrow Transplantation.

Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

J. Byrd, C. Hofmeister, R. Garzon, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma

M. Caligiuri, C. Hofmeister, S. Jagannath, 2015, Clinical Cancer Research.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

M. Caligiuri, C. Hofmeister, D. Benson, 2011, Blood.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant

C. Hofmeister, A. Ruppert, L. Andritsos, 2015, Leukemia & lymphoma.

Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

Jeffrey S. Johnston, M. Grever, C. Hofmeister, 2013, Clinical Pharmacokinetics.

Graft-versus-host disease of the skin: life and death on the epidermal edge.

C. Hofmeister, P. Stiff, B. Nickoloff, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

raft-versus-Host Disease of the Skin : Life and Death n the Epidermal Edge

C. Hofmeister, P. Stiff, B. Nickoloff, 2004 .

Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM)

H. Goldschmidt, C. Hofmeister, P. Moreau, 2018, Blood.

Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).

C. Hofmeister, D. Benson, Y. Efebera, 2019, Archives of hematology and blood diseases.

Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein–Barr virus DNA PCR

C. Hofmeister, D. Benson, S. Devine, 2007, Bone Marrow Transplantation.

A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma

C. Hofmeister, Xiwen Ma, E. Baloglu, 2021, American journal of hematology.

Lenalidomide after stem-cell transplantation for multiple myeloma.

K. Owzar, C. Hofmeister, R. Vij, 2012, The New England journal of medicine.

CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma

M. Caligiuri, K. Ghoshal, C. Hofmeister, 2013, Leukemia.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019 .

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

J. Byrd, L. Cascione, C. Hofmeister, 2014, Oncotarget.

MicroRNAs activate natural killer cells through Toll-like receptor signaling.

M. Caligiuri, K. Ghoshal, C. Hofmeister, 2013, Blood.

Daratumumab in multiple myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2019, Cancer.

The potential of miRNAs as biomarkers for multiple myeloma

C. Hofmeister, F. Pichiorri, A. Rocci, 2014, Expert review of molecular diagnostics.

Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation

C. Hofmeister, W. Sadee, M. Phelps, 2020, AntiCancer Research.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

C. Hofmeister, A. Krishnan, S. Singhal, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Michael A. Freitas, Guido Marcucci, Stefano Volinia, 2013, The Journal of experimental medicine.

MiR-16 regulates crosstalk in NF-kB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

J. Keats, P. L. Bergsagel, C. Hofmeister, 2019, JCI insight.

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Michael A. Freitas, J. Byrd, C. Hofmeister, 2016, Journal of proteomics.

Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma

J. Keats, C. Hofmeister, S. Lonial, 2021, Clinical Cancer Research.

Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Pharmacotherapy.

Renal cell cancer

C. Hofmeister, J. Sosman, Joseph I. Clark, 2006 .

Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.

C. Hofmeister, E. Kraut, D. Benson, 2008, Leukemia research.

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

M. Caligiuri, J. Byrd, C. Hofmeister, 2010, Blood.

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

A. Chinnaiyan, D. Auclair, P. L. Bergsagel, 2022, Nature Communications.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents

C. Hofmeister, G. Phillips, D. Benson, 2012, Hematological oncology.

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

C. Shapiro, C. Hofmeister, E. Hade, 2021, Cancer Chemotherapy and Pharmacology.

Tocilizumab for steroid refractory acute graft-versus-host disease

C. Hofmeister, L. Andritsos, D. Benson, 2016, Leukemia & lymphoma.

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

Ninety-minute daratumumab infusion is safe in multiple myeloma

C. Hofmeister, D. Benson, Y. Efebera, 2017, Leukemia.

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Blood Cancer Journal.

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred

C. Hofmeister, P. Hawkins, D. Benson, 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021, Blood cancer discovery.

Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation and MyD88-mutant progenitors precede malignancy in Waldenstrom macroglobulinemia

C. Hofmeister, S. Lonial, M. Dhodapkar, 2021 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant

C. Hofmeister, F. Pichiorri, M. Phelps, 2017, Molecular carcinogenesis.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

TTP disease course is independent of myeloma treatment and response

C. Hofmeister, D. Benson, M. Jin, 2010, American journal of hematology.

Unique pattern of renal κ light chain amyloid deposition with histiocytic transdifferentiation of tubular epithelial cells.

C. Hofmeister, S. Brodsky, T. Nadasdy, 2012, The American journal of surgical pathology.

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma

C. Hofmeister, S. Lonial, D. Siegel, 2017, Leukemia.

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

C. Hofmeister, S. Lonial, J. Laubach, 2015 .

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

J. Keats, C. Hofmeister, S. Lonial, 2021, Blood.

Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma

J. Byrd, C. Hofmeister, N. Heerema, 2010, Leukemia & lymphoma.

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

J. Keats, C. Hofmeister, A. Krishnan, 2019, bioRxiv.

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

J. Byrd, C. Hofmeister, D. Benson, 2019, Journal of geriatric oncology.

Population pharmacokinetics of lenalidomide in patients with B‐cell malignancies

M. Grever, J. Byrd, C. Hofmeister, 2019, British Journal of Clinical Pharmacology.

A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

M. Grever, C. Hofmeister, G. Nuovo, 2014, Clinical Cancer Research.

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

A. Hui, C. Hofmeister, M. Liedtke, 2013 .

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

C. Hofmeister, G. Lozanski, L. Andritsos, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2020, Blood Cancer Journal.

Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells

C. Hofmeister, Qi-En Wang, S. Devine, 2014, Clinical Cancer Research.

CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered NK Cells and T Cells Enhance In Vitro and In Vivo Anti-Tumor Activity Against Human Multiple Myeloma

M. Caligiuri, K. Ghoshal, C. Hofmeister, 2013 .

FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome.

C. Hofmeister, Zhijin Fan, S. Devine, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Journal of Clinical Oncology.

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

J. Keats, C. Hofmeister, A. Krishnan, 2018, Oncoimmunology.

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

R. Advani, J. Leonard, C. Hofmeister, 2010 .

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

High-risk myeloma: when to transplant-or not.

C. Hofmeister, S. Lonial, F. Cavallo, 2014, Seminars in oncology.

Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?

C. Hofmeister, L. Andritsos, D. Benson, 2018, Bone Marrow Transplantation.

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma

C. Hofmeister, E. Hade, M. Phelps, 2017, Leukemia & lymphoma.

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

C. Hofmeister, M. Cotreau, A. Tolcher, 2014, British Journal of Cancer.

The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma.

C. Hofmeister, E. Hade, D. Benson, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients

C. Hofmeister, L. Andritsos, D. Benson, 2018, Bone Marrow Transplantation.

Registering a CD38 antibody upfront for multiple myeloma

C. Hofmeister, S. Lonial, J. Kaufman, 2019, The Lancet.

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Derek A. West, Michael A. Freitas, M. Grever, 2010, PloS one.

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Don M. Benson, C. Hofmeister, H. Kwon, 2013, Cancer Immunology, Immunotherapy.

Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2011 .

A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy

C. Hofmeister, M. Phelps, M. Poi, 2021, AntiCancer Research.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

J. Byrd, A. Palumbo, L. Cascione, 2014, Leukemia.

Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.

C. Hofmeister, K. Wood, G. Phillips, 2012, Clinical lymphoma, myeloma & leukemia.

The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics

C. Hofmeister, D. Sborov, Desiree Jones, 2015 .

Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma

F. Gao, C. Hofmeister, R. Vij, 2022, Leukemia.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

C. Hofmeister, A. Jakubowiak, T. Zimmerman, 2009 .

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM).

K. Anderson, C. Hofmeister, P. Richardson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Venetoclax ex vivo functional profiling predicts improved progression-free survival

C. Hofmeister, S. Lonial, M. Dhodapkar, 2022, Blood Cancer Journal.

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

M. Dimopoulos, C. Hofmeister, J. Miguel, 2017 .

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

H. Goldschmidt, C. Hofmeister, P. Voorhees, 2017 .

Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer

C. Hofmeister, B. Emami, G. Petruzzelli, 2009, American journal of clinical oncology.

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

F. Gao, C. Hofmeister, R. Vij, 2019, Blood.

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma

J. Byrd, C. Hofmeister, G. Nuovo, 2016, Molecular Cancer Therapeutics.

Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

J. Shah, M. Dimopoulos, C. Hofmeister, 2020, Leukemia.

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

K. Owzar, C. Hofmeister, P. Richardson, 2009 .

Mucosal protection by cytokines.

C. Hofmeister, P. Stiff, 2005, Current hematology reports.

Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

C. Hofmeister, S. Lonial, J. Laubach, 2013 .

Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma

C. Hofmeister, D. Benson, S. Devine, 2010, Leukemia & lymphoma.

Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma

C. Hofmeister, M. Phelps, M. Poi, 2014 .

Characterization of multiple myeloma vesicles by label‐free relative quantitation

Michael A. Freitas, C. Hofmeister, F. Pichiorri, 2013, Proteomics.

African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction

C. Hofmeister, S. Lonial, J. Kaufman, 2022, Blood.

Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.

C. Hofmeister, S. Jagannath, S. Lonial, 2013 .

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma

C. Hofmeister, E. Baloglu, W. Senapedis, 2017 .

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

C. Hofmeister, A. Oriol, A. Yee, 2022, Blood.

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma

C. Hofmeister, S. Lonial, M. Dhodapkar, 2018, Blood.

TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients

C. Hofmeister, D. Vesole, R. Abonour, 2015 .

Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial

C. Hofmeister, R. Vij, J. Kaufman, 2018, Blood.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis

C. Hofmeister, S. Jagannath, S. Lonial, 2012 .

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

C. Hofmeister, A. Chanan-Khan, Kelvin P Lee, 2009 .

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for 30-Day Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma

C. Hofmeister, A. Ruppert, L. Andritsos, 2014, Bone Marrow Transplantation.

Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma

C. Hofmeister, T. Zimmerman, P. Richardson, 2008 .

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Shang-Yi Huang, Ajai Chari, Chb, 2013 .

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

D. Auclair, J. Keats, C. Hofmeister, 2019, Nature Communications.

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

C. Hofmeister, B. Barwick, D. Rondelli, 2020 .

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

J. Byrd, L. Cascione, C. Hofmeister, 2015, OncoTarget.

Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.

M. Grever, J. Byrd, C. Hofmeister, 2012 .

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant

B. Fridley, C. Hofmeister, M. Poi, 2023, Haematologica.

A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency.

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, Journal of Clinical Oncology.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

C. Hofmeister, S. Singhal, Rashmi Kumar, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

C. Hofmeister, S. Lonial, M. Dhodapkar, 2023, The Journal of clinical investigation.

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

C. Hofmeister, Jack Benner, D. Benson, 2015 .

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

C. Hofmeister, A. Krishnan, S. Singhal, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

Melissa L. Kemp, C. Hofmeister, S. Lonial, 2019, JCI insight.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

M. Caligiuri, J. Byrd, C. Hofmeister, 2010, Blood.

Reply to N. Chen et al

C. Hofmeister, M. Phelps, Xiaoxia Yang, 2012 .

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Michael A. Freitas, J. Byrd, C. Hofmeister, 2016, Journal of proteomics.

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

B. Barlogie, J. Shaughnessy, R. Fonseca, 2010, Mayo Clinic proceedings.

MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).

C. Hofmeister, S. Lonial, D. Siegel, 2013 .

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

C. Hofmeister, S. Trudel, D. Reece, 2018, Blood.

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin’s lymphomas

C. Hofmeister, L. Andritsos, D. Benson, 2019, Bone Marrow Transplantation.

Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections.

A. Sette, C. Hofmeister, S. Lonial, 2022, Blood cancer discovery.

Molecular Carcinogenesis

C. Hofmeister, M. Phelps, Danxin Wang, 2019 .

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

J. Leonard, C. Hofmeister, A. Chanan-Khan, 2017, The Lancet. Haematology.

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Umar Syed, G. Mulligan, C. Hofmeister, 2022, Blood.

Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected

C. Hofmeister, D. Benson, Y. Efebera, 2016 .

Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan‐based reduced toxicity conditioning

C. Hofmeister, R. Garzon, G. Phillips, 2011, Hematological oncology.

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma

C. Hofmeister, E. Hade, G. Lozanski, 2015, Leukemia & lymphoma.

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study

C. Hofmeister, L. Andritsos, D. Benson, 2014, Supportive Care in Cancer.

Downregulation of PA28 alpha induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

C. Hofmeister, S. Lonial, B. Barwick, 2022 .

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

C. Hofmeister, G. Lozanski, L. Andritsos, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure

C. Hofmeister, S. Jagannath, D. Siegel, 2012 .